Signavio GmbH – a provider of SaaS-based business process and decision management technology – announced on December 17, 2015 the completion of a €31 million minority investment from global growth equity investor Summit Partners. The investment will help Signavio expand its international footprint and continue its very strong growth trajectory. Read more
Jenetric GmbH announced that it has received an undisclosed amount in a Series B funding. “The whole team impressed us with their determination, with their performance and with their ambitious plans for the future. We are looking forward to accompanying the further development,” says Karin Rabe, Investment Manager of bm|t, the holding company of the Free State of Thuringia. Also the Business Angel Prof. Dr. Franz Schmidt and the early-stage investor “High-Tech Gründerfonds (HTGF)” stay financially engaged and thus enable the production and global distribution of LIVETOUCH® quattro. Dr. Ansgar Kirchheim, Investment Manager at HTGF: “After the successful FBI certification and the start of production, we are pleased to support the large-scale market entry of JENETRIC .”
JENETRIC GmbH was founded in 2014 in Jena, Germany – a location famous for cutting-edge optical technology – by engineers with significant experience in fingerprint technology and special focus on the development of biometric systems. The multidisciplinary team includes hardware and software specialists as well as production and sales professionals. The company follows a holistic approach in its product development with a clear and strong focus on customer requirements and with the ambitious goal of enhancing living and working conditions by using biometric systems.
REVOBOTIK GmbH, a company that develops and distributes robots for mass production, shows how to set new standards in an established market. The remarkable thing is that their robots significantly outperform previous systems in terms of payload and speed; this means that the number of robots in a machine can be greatly reduced, resulting in savings both on costs and space. High-Tech Gründerfonds (HTGF) is using seed financing to acquire an interest in this unique technology. Read more
Myelo Therapeutics announced that it has raised an undisclosed amount of Series B funding. The financing round was co-led by venture capital investors IBB Beteiligungsgesellschaft mbH with its VC Fonds Technologie Berlin and Eckert Life Science Accelerator GmbH, as well as the pharmaceutical company JSC Valenta Pharmaceuticals and Myelo001 inventor Dr. Vladimir Nebolsin. The successful closing of its Series B financing round will enable Myelo Therapeutics to complete the clinical proof of concept for Myelo001 in CIN and expand its preclinical research of Myelo001 to new areas.
Dirk Pleimes, Managing Director and Chief Medical Officer, stated, “Myelo001 offers a novel, orally applied treatment of chemotherapy-induced neutropenia and bone marrow suppression. New adjunct treatment options are needed for cancer patients to allow the full chemotherapy dose to be maintained and to decrease the incidence of infections. “ Till Erdmann, Managing Director responsible for business development, declared, “In less than three years after founding the company, we brought our first development compound to phase II clinical stage. Our scientific progress and the company’s increase in value are confirmed by several outstanding institutional and strategic investors that participated in our Series B financing round. With a well-defined development strategy for an innovative compound, we are targeting an indication with high unmet medical need, no significant treatment innovation for over 20 years, and a market size of USD 6 billion.”
“Myelo001 has shown its potential in several indications, such as Chemotherapy- and Radiotherapy-induced Myelosuppression, as well as the prevention and treatment of respiratory viral infections. I am pleased that we are now starting clinical development in Chemotherapy-induced Neutropenia as a first step,” says Dr. Vladimir Nebolsin, the medicinal chemist who first synthesized Myelo001. “Myelo Therapeutics’ management convinced us with the significant progress they have achieved so far in a short time period, as well as a well-executed development strategy for an innovative compound with high market potential,” said Christian Seegers, senior investment manager of the IBB Beteiligungsgesellschaft. “We are convinced that financing Myelo Therapeutics GmbH further promotes the strong pharmaceutical environment in Berlin.”
Myelo Therapeutics GmbH, a pharmaceutical company, develops conventional chemotherapeutic agents for use in anticancer treatments. It develops myelo001, a small molecule for the treatment of patients with chemotherapy-induced neutropenia and thrombocytopenia. The company is based in Berlin, Germany.
A consortium of investors has closed investment Round A for Multiphoton Optics GmbH’s High-Precision 3D Lithography Platform which closes the gap between classical 3D printing and optical lithography. Investors are Sack & Kiesselbach GmbH, High-Tech Gründerfonds GmbH, Bayern Kapital GmbH, the Fraunhofer Gesellschaft e.V. and a consortium of Business Angels with Dr. Ruth Houbertz, Dr. Moritz Esslinger, and Dr. Boris Neubert. Read more
GoEuro Corp. announced that it has raised $45 million in its series B round of funding led by new investor Goldman Sachs Group, Merchant Banking Division on December 9, 2015. The transaction also included participation from new investors Atomico Investment Holdings Limited, Yuri Milner, Tom Stafford, Sebastian Siemiatkowski, and Ilkka Paananen, and existing investors Battery Ventures, New Enterprise Associates, and Lakestar Advisors GmbH, a fund managed by Hommels Holding GmbH. The company has raised a total of $76 million in funding to date. Read more
Younicos has signed agreements for $50 million in growth capital to further scale its deployment of intelligent energy storage solutions. The funding comes from a consortium that includes First Solar, Inc., a global provider of solar energy solutions and Grupo ECOS, a sustainable investment-focused private equity firm. They join an undisclosed strategic lead investor. According to GTM Research, this is the largest investment in a technology independent energy storage provider in 2015. Read more
Crowd Guru GmbH announced that it has received a six-figure amount in an equity round of funding on December 9, 2015. The transaction included participation from new investor Müller Medien GmbH & Co. KG and returning investor, VC Fonds Kreativwirtschaft Berlin, a fund managed by IBB Beteiligungsgesellschaft mbH. As part of the transaction, existing investor Wellington Ventures and other business angels sold their shares to the new investor Müller Medien GmbH & Co. KG. Read more
The 3D printing company trinckle 3D GmbH (“trinckle”), based in Hennigsdorf near Berlin, has completed a financing round. In this process, it gained KfW Bankengruppe (“KfW”) and redpartners gmbh (“redpartners”) as new investors. A business angel also came on board as a new investor in addition to the existing shareholder BFB Frühphasenfonds Brandenburg GmbH (“BFB”). The latter has made use of its conversion rights from a subordinated loan and will therefore continue to hold a 15% stake in trinckle. Read more
Medexo announced that has received $1.3m in an equity round of funding on November 23, 2015. The transaction included participation from new investors, Thanyapura Phuket and individual investors, Rüdiger Will and Klaus Tschütsch, former prime minister of Liechtenstein.
Medexo is an e-Health platform that connects patients with independent medical professionals. The company is based in Berlin. Medexo announced to use the funds to finance the international roll out of the platform. Medexo is currently available in German and English.
Thanyapura Phuket is an Asian health and sports company.